ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?

Cardiology Journal

Volumn 19, Issue 1, 2012, Pages 4-10

  Tendera, Michał ^a   Syzdół, Marcin ^a   Parma, Zofia ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; Rivaroxaban; Stroke prevention

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG EFFICACY; DRUG FATALITY; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; STROKE; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; MORPHOLINES; PATIENT SELECTION; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; STROKE; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84856799028     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: 10.5603/CJ.2012.0002     Document Type: Article

References (27)

1. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics 2010 update: A report from the American Heart Association. Circulation, 2010; 121: e46-e215.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke, 1991; 22: 983-988.
3. Marini C, De Santis F, Sacco S et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: Results from a population-based study. Stroke, 2005; 36: 1115-1119.
4. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med, 1994; 154: 1449-1457.
5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007; 146: 857-867.
6. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Eur Heart J, 2010; 31: 2369-2429.
7. Hylek EM, Skates SJ, Sheehan MA et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med, 1996; 335: 540-546.
8. Matchar DB, Samsa GP, Cohen SJ et al. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: Results of the managing anticoagulation services trial. Am J Med, 2002; 113: 42-51.
9. Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet, 2007; 370: 493-503.
10. Friberg L, Hammar N, Ringh M et al. Stroke prophylaxis in atrial fibrillation: Who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J, 2006; 27: 1954-1964.
11. Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol, 2007; 27: 1238-1247.
12. Wann LS, Curtis AB, Ellenbogen KA et al. 2011 ACCF/AHA/ /HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol, 2011; 57: 1330-1337.
13. Blech S, Ebner T, Ludwig-Schwellinger E et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos, 2008; 36: 386-399.
14. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther, 2005; 78: 412-421.
15. Raghavan N, Frost CE, Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos, 2009; 37: 74-81.
16. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009; 361: 1139-1151.
17. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365: 883-891.
18. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011; 365: 981-992.
19. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Redford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA, 2001; 285: 2864-2870.
20. Connolly SJ, Ezekowitz MD, Yusuf S et al. Newly identified events in the RE-LY trial. N Engl J Med, 2010; 363: 1875-1876.
21. Samama MM, Martinoli JL, LeFlem L et al. Assessment of laboratory assays to measure rivaroxaban: An oral, direct factor Xa inhibitor. Thromb Haemost, 2010; 103: 815-825.
22. Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet, 2010; 376: 975-983.
23. Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation, 2011; 123: 2363-2372.
24. Reuters Health E-line, 27 October, 2011.
25. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. A randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 2011; 124: 1573-1579.
26. Bauer KA. New anticoagulants: Anti IIa vs anti Xa Is one better? J Thromb Thrombolysis, 2006; 21: 67-72.
27. Freeman JV, Zhu RP, Owens DK et al. Cost effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med, 2011; 154: 1-11.